Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
OrbiMed
company
About
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
- 101 - 250
Highlights
Details
- Industries
- Angel Investment,Financial Services,Health Care
- Founded date
- Jan 1, 1989
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Investor Type
- PE
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.
Investments
Number of Investments
Number of Lead Investments
65
26
OrbiMed has made 65 investments. Their most recent investment was on
Dec 7, 2022, when Apogee Therapeutics raised $149M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 7, 2022
Apogee Therapeutics
|
Series B | $149M | Biotechnology | — |
|
Nov 14, 2022
MBX Biosciences
|
Series B | $115M | Biotechnology | — |
|
Oct 11, 2022
Treeline Biosciences
|
Series A | $261.26M | Biotechnology | — |
|
Sep 12, 2022
Adaptive Biotechnologies
|
Post-IPO Debt | $125M | Biotechnology | Yes |
|
Jun 30, 2022
X4 Pharmaceuticals
|
Post-IPO Equity | $55M | Biotechnology | — |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
